Skip to main content
    I

    InspireMD Inc (NSPR)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.60
    -0.04 (-6.85%)

    Market Cap: $30.13M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    InspireMD Inc (NSPR) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    InspireMD (NSPR) trades at 4.9x sales and 2.4x book value. Its P/S of 4.9x is below its 5-year median of 7.7x. Its forward P/E is 11.7x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E11.7x
    Price to sales4.9x
    Price to book2.4x
    PEGN/A
    FCF yield-82.7%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 140.0% above 1.0x.

    MultipleCurrent5-year median10-year median
    P/S4.9x7.7xN/A
    P/B2.4x1.8x1.0x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 104 months (10-year).

    Valuation History

    Over the 7 of the 10 year ends shown that have a P/S, its P/S ranged from 0.5x in 2019 to 15.5x in 2024.

    Year endPriceP/SP/B
    2025$1.7812.5x2.4x
    2024$2.6315.5x3.6x
    2023$2.818.0x1.7x
    2022$0.861.3x0.4x
    2021$3.024.9x0.7x
    2020$5.111.2x1.1x
    2019$16.190.5x0.9x
    2018$119.12N/A0.8x
    2017$3,407.39N/A0.3x
    2016$65,526.68N/AN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NSPR

    What is NSPR's forward P/E ratio?

    InspireMD has a forward P/E ratio of 11.7x.

    Is NSPR stock overvalued?

    GNG's valuation label for NSPR is Fairly valued.

    What is NSPR's price to sales ratio?

    InspireMD has a price to sales ratio of 4.9x.